Relationship between heart failure treatment and development of worsening renal function among hospitalized patients.

[1]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.

[2]  C. O'connor,et al.  The prognostic importance of different definitions of worsening renal function in congestive heart failure. , 2002, Journal of cardiac failure.

[3]  John A Spertus,et al.  Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. , 2002, Journal of the American College of Cardiology.

[4]  W. Rand,et al.  Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.

[5]  I. Shapira,et al.  The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. , 2001, Journal of the American College of Cardiology.

[6]  A. Charlesworth,et al.  Renal function, neurohormonal activation, and survival in patients with chronic heart failure. , 2000, Circulation.

[7]  I. Shapira,et al.  The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. , 2000, Journal of the American College of Cardiology.

[8]  H. Krumholz,et al.  Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure. , 2000, The American journal of cardiology.

[9]  G. Bakris,et al.  Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? , 2000, Archives of internal medicine.

[10]  M. Domanski,et al.  The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. , 2000, Journal of the American College of Cardiology.

[11]  E. Philbin,et al.  Clinical outcomes in heart failure: report from a community hospital-based registry. , 1999, The American journal of medicine.

[12]  L. Stevenson,et al.  Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. , 1999, American heart journal.

[13]  Bertram Pitt,et al.  Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.

[14]  F. Locatelli,et al.  Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency , 1996 .

[15]  D. Brater,et al.  Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure , 1995, Clinical pharmacology and therapeutics.

[16]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[17]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[18]  D. Brater,et al.  Furosemide in patients with heart failure: Shift in dose‐response curves , 1980, Clinical pharmacology and therapeutics.

[19]  L. Benet,et al.  Pharmacokinetics of furosemide in patients with congestive heart failure. , 1979, Pharmacology.